Navigation Links
VIVUS Reports Third Quarter 2009 Highlights and Financial Results
Date:11/3/2009

September 30, December 31, 2009 2008* ---- ---- (unaudited) Current assets: Cash and cash equivalents $127,819 $66,121 Available-for-sale securities 99,096 121,789 Accounts receivable, net 2,347 4,157 Inventories, net 2,760 3,041 Prepaid expenses and other assets 3,634 3,744 ----- ----- Total current assets 235,656 198,852 Property and equipment, net 6,104 6,726 Restricted cash 700 700 Available-for-sale securities - 1,344 Total assets $242,460 $207,622 ======== ======== Current liabilities: Accounts payable $7,208 $17,205 Deferred revenue 462 31,858 Accrued and other liabilities 14,840 14,909 ------ ------ Total current liabilities 22,510 63,972 Notes payable-net of current portion 20,104 11,177 Deferred revenue 914 1,260 --- ----- Total liabilities 43,528 76,409
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...
(Date:6/18/2013)... June 18, 2013 ... announced the addition of the "Injectable ... & Nanoparticles], Devices [Disposables & Reusable, Fillable ... Injectors] & Therapeutics [Diabetes & Oncology] - ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ...
(Date:6/18/2013)... June 18, 2013 Inflamax Research ... of Concept and Phase I-IV clinical trials, announced ... with Northern Air Environmental Technologies (NAET), a specialty ... deployment, monitoring, and servicing of mobile Environmental Exposure ... clinical trials. , Inflamax Research ...
(Date:6/18/2013)... June 18, 2013 On June 11, ... released a final decision memorandum concluding that FDG ... subsequent management of anti-tumor strategy, and the agency ... National Oncological PET Registry (NOPR) was developed jointly by ... projects under the Coverage with Evidence Development (CED) program ...
Breaking Biology Technology:Bioinformatics Market Worth $7.5 Billion by 2017 2Bioinformatics Market Worth $7.5 Billion by 2017 3Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 2WMIS Welcomes CMS Decision: Expanding Coverage for FDG-PET and Ending NOPR Data 3
... CHARLOTTESVILLE, Virginia, June 23 ... targeting epilepsy, has shown,positive results in the Kainic ... existing drug that Biovista repositioned in epilepsy, exhibits,both ... induced a statistically significant decrease of epileptic activity ...
... to Nearly $4 Million , , BETHPAGE, N.Y., ... largest private supporter of pancreatic cancer research, today announced its ... six leading research centers for early diagnostic tests and better ... , Lustgarten is expected to award nearly $4 million ...
... , SEATTLE, June 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... a division of Wyeth (NYSE: WYE ), ... collaboration agreement with Trubion to extend the research period ... Under the terms of the research period extension, Wyeth,s ...
Cached Biology Technology:Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy 2The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:6/18/2013)... $12.7 million to match nine academic research groups ... explore new treatments for patients in eight disease ... schizophrenia. The collaborative pilot initiative, called Discovering New ... the National Center for Advancing Translational Sciences (NCATS) ... The process of developing a new therapeutic is ...
(Date:6/18/2013)... June 18, 2013: The Association for Molecular Pathology is ... American Societies for Experimental Biology (FASEB) on July 1, ... on June 3, 2013. , The 26 constituent ... share a common vision for the advancement of research ... and translational research is more important now than ever," ...
(Date:6/18/2013)... that between 5% and 10% of breast and ovarian ... that these tumours are attributable to inherited mutations from ... In patients with these mutations, PARP inhibitors, which are ... make them a new option for personalised cancer treatment, ... indicate that a fraction of these patients generate resistance ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... Here,s good news for anyone trying to lose weight ... of a weight loss drug that may revolutionize how we ... in the September 2010 print issue of The FASEB ... "Sprouty," responsible for regulating body fat and bone mass. Then ...
... new research from North Carolina State University shows that a ... past 3,000 years has actually increased in size, despite ... area. "What we,ve found indicates that human activity does ... negative impact on a species even a species that ...
... study of the body system that deals with Americans, love affair ... up hypertensive and how to better treat them. A team ... Utah and the University of Texas at San Antonio is looking ... what they do to eliminate it. The work is funded by ...
Cached Biology News:Scientists discover new protein that gets to the roots of obesity and osteoporosis 2Archaeological study shows human activity may have boosted shellfish size 2System for eliminating salt may point to new antihypertensives 2System for eliminating salt may point to new antihypertensives 3
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... FROM LIGHT. Useful in cell activation experiments when calcium ... TLC. Soluble in DMSO or EtOH. For ... stock in DMSO is recommended. Microliter amounts of this ... rapid mixing (e.g. 10 μl into 5 ml of ...
... poorly to Protein A and, until recently, no ... step IgM purification. Standard methods for IgM purification ... not effective for removing all of the major ... Pierce has developed an easy-to-use affinity ...
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... FROM MOISTURE. Protein synthesis inhibitor. Inhibits ... nascent polypeptide chains. Induces DNA fragmentation ... leukemia cells. Purity: ≥98% by ...
Biology Products: